Computer-Aided Drug Design in Modern Pharmaceutical Research: An In-Silico Perspective

Deep Jyoti Shah, Mahesh Kumar Yadav, Astha Topno, Shivam Kashyap, Jiten Goray, Ajay Kumar, Amisha Kumari, Ayush Kumar Verma, Gangadhar Singh, Karan Kumar, Manshi Kumari, Priti Payal Jha, Rakhi Kumari, Sakshee Goswami, Sudarshan Rawani, Suraj Kumar, Anjali Prasad, Ashish Ranjan Yaduvendu, Dhananjay sahu, Amit Kumar Prajapati, Biplop Debnath,

doi:10.5281/zenodo.17458222

Review Paper | Open Access
Volume 02 | Issue 10 | Article Id IJSRT/250310103

Computer-Aided Drug Design in Modern Pharmaceutical Research: An In-Silico Perspective
Deep Jyoti Shah* Mahesh Kumar Yadav Astha Topno Shivam Kashyap Jiten Goray Ajay Kumar Amisha Kumari Ayush Kumar Verma Gangadhar Singh Karan Kumar Manshi Kumari Priti Payal Jha Rakhi Kumari Sakshee Goswami Sudarshan Rawani Suraj Kumar Anjali Prasad Ashish Ranjan Yaduvendu Dhananjay sahu Amit Kumar Prajapati Biplop Debnath
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India

Abstract

Computer-Aided Drug Design (CADD) has become an indispensable component of the current pharmaceutical research and has changed the established paradigms of drug discovery. This extensive overview of the research analyses the basic concepts, protocols, and uses of CADD in an in-silico viewpoint. We highlight the key computational techniques, including molecular docking, pharmacophore modelling, quantitative structure-activity relationship (QSAR) analysis, molecular dynamics simulation, and part-based drug designs, including the structural-based drug design (SBDD) and ligand-based drug design (LBDD) approaches. The integration of computational chemistry, structural biology, and bioinformatics has enabled reasonable design of therapeutic agents, including improved efficacy, selectivity, and reduction of toxicity. Some of the theoretical foundations of CADD methodologies, their practical uses in the fields of hit identification, lead optimization, and ADMET prediction, and case studies representing successful translation of computational predictions to clinical candidates are discussed. There are severe issues such as limitations on accuracy, computational cost, protein flexibility and validation concerns, that are tackled. The prospects that involve the implementation of artificial intelligence, quantum mechanical models, and cloud computing are examined. CADD remains a developing technology that is playing a vital role as a bridge between the computational sciences and the experimental pharmaceutical research to fast-track drug discovery and minimize expenses and the need of animal testing.

Keywords

Computer-Aided Drug Design, Molecular Docking, QSAR, Pharmacophore Modelling, Structure-Based Drug Design, Virtual Screening, In Silico Methods

Introduction

1.1 The Evolution of Drug Discovery

The discovery of traditional medicine was largely dependent on sudden observation, natural product screening, and rugged trial-and-error methods. Detection of therapeutic agents through systematic random screening of chemical libraries, although sometimes successful, proved unskilled, expensive, and timely. The average cost for bringing a new drug to market approval from the initial discovery exceeds 2.6 billion USD over 12-15 years; success rates remain unexpectedly low—about 90% of drug candidates entering clinical trials fail to achieve regulatory approval. The molecular revolution of biology, with the exponential growth of computational energy, has fundamentally transformed pharmaceutical research. Explanation of disease processes at molecular and genetic levels, determining the three-dimensional structure of biological macromolecules through X-ray crystallography, and the development of sophisticated computational algorithms enabled reasonable, knowledge-based methods in the design of medicine. Computer-aided drug design represents this paradigm shift, using computational methods to guide and accelerate the discovery and optimization of therapeutic agents [1].

1.2 Principles of Computer-Aided Drug Design

CADD includes computational techniques that facilitate drug discovery by molecular interaction prediction, binding affinity estimation, pharmacological property evaluations, and prioritizing compounds for experimental validity. The underlying basic fundamental of CADD is that drugs interact with specific biological goals and apply therapeutic effects—usually proteins such as enzymes, receptors, ion channels, or nucleic acid. The three-dimensional structure of targets and molecular determinants of ligand-target interactions enable rational design of molecules with the desired binding properties.

The CADD method is usually classified into two complementary methods:

Structure-based drug design (SBDD): This method uses three-dimensional structural information of biological targets, which are obtained through experimental methods or computational modelling. SBDD techniques predict how small molecules are bound to target active sites, enabling rational changes to increase affinity and specificity. The main SBDD method includes molecular docking, de novo design, and structure-based virtual screening [2].

Ligand-based drug design (LBDD): When target structural information is unavailable or limited, LBDD uses knowledge of the molecules known to interact with the target. By analysing structural features, physical and chemical properties, and activity profiles of known ligands, LBDD methods detect patterns related to biological activities and use these patterns to design or identify new active compounds. The original LBDD method includes pharmacophore modelling, QSAR analysis, and similar searches [3]. Integration of SBDD and LBDD methods, complementarily combined with computational techniques, produces a wide workflow capable of dealing with various challenges across the pipeline.